{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:00Z","timestamp":1794047520594,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2025.288411","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:56:46Z","timestamp":1761206206000},"page":"1443-1448","source":"Crossref","is-referenced-by-count":5,"title":["The impact of daratumumab-containing induction on stem cell mobilization, collection and engraftment in newly diagnosed multiple myeloma: results of the prospective DILEMMA study"],"prefix":"10.3324","volume":"111","author":[{"given":"Caterina Giovanna","family":"Valentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Ladiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Za","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Teofili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"88207","doi-asserted-by":"crossref","unstructured":"Cavo M, Gay F, Beksac M. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalanprednisone, with or without bortezomib-lenalidomidedexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/ HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020; 7(6):e456-468.","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"88208","doi-asserted-by":"crossref","unstructured":"Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E. The EBMT Handbook Hematopoietic Cell Transplantation and Cellular Therapies. 2024. Publisher Full Text|","DOI":"10.1007\/978-3-031-44080-9"},{"key":"88209","doi-asserted-by":"crossref","unstructured":"Sgherza N, Musto P. Effects of daratumumab on hematopoietic stem cells in patients with multiple myeloma who are planned to receive autologous transplantation: what\u2019s the relevance?. Mediterr J Hematol Infect Dis. 2024; 16(1):e2024073.","DOI":"10.4084\/MJHID.2024.073"},{"key":"88210","doi-asserted-by":"crossref","unstructured":"Seth A, Murray D, Buadi FK. Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti-CD38 mAb. Eur J Haematol. 2023; 111(2):318-321.","DOI":"10.1111\/ejh.14008"},{"key":"88211","doi-asserted-by":"crossref","unstructured":"Hulin C, Offner F, Moreau P. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica. 2021; 106(8):2257-2260.","DOI":"10.3324\/haematol.2020.261842"},{"key":"88212","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945.","DOI":"10.1182\/blood.2020005288"},{"key":"88213","doi-asserted-by":"crossref","unstructured":"Chhabra S, Callander NS, Costa LJ. Stem cell collection with daratumumab (DARA)-based regimens in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients (pts) in the Griffin and Master Studies. Blood. 2021; 138(Suppl 1):2852.","DOI":"10.1182\/blood-2021-149028"},{"key":"88214","doi-asserted-by":"crossref","unstructured":"Valentini CG, Pellegrino C, Putzulu R. Day -1 CD34+ cells and platelet count predict the number of apheresis in poor-mobilizer patients rescued by plerixafor. J Clin Med. 2023; 12(2):618.","DOI":"10.3390\/jcm12020618"},{"key":"88215","doi-asserted-by":"crossref","unstructured":"Fokkema C, Appelman MK, Veldhoen N. Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab. Bone Marrow Transplant. 2025; 60(11):1496-1498.","DOI":"10.1038\/s41409-025-02681-4"},{"key":"88216","doi-asserted-by":"crossref","unstructured":"Duan H, Jiang Q, Liu L. Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma. Ann Hematol. 2024; 103(10):3839-3853.","DOI":"10.1007\/s00277-024-05683-2"},{"key":"88217","doi-asserted-by":"crossref","unstructured":"Musto P, Simeon V, Grossi A. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell\u2019Adulto Multiple Myeloma Working Party study. Stem Cell Res Ther. 2015; 6(1):64.","DOI":"10.1186\/s13287-015-0033-1"},{"key":"88218","doi-asserted-by":"crossref","unstructured":"Liberatore C, Perini T, Passeri C. Higher cyclophosphamide dose grants optimal stem cell collection after daratumumab-based induction in multiple myeloma. Haematologica. 2023; 108(12):3502-3505.","DOI":"10.3324\/haematol.2023.283452"},{"key":"88219","doi-asserted-by":"crossref","unstructured":"Uzun D, Paul JM, Jensen A. The impact of Anti-CD38 MAb therapy on stem-cell mobilization yields in patients with newly diagnosed multiple myeloma (NDMM) referred from community and academic oncology practices: single center, real world data 2021-2024. Transplant Cell Ther. 2025; 31(12):1006.e1-1006.e11.","DOI":"10.1016\/j.jtct.2025.08.014"},{"key":"88220","doi-asserted-by":"crossref","unstructured":"Passos RMA, Marcolino MAZ, Passos JA. Cost-effectiveness of preemptive plerixafor versus rescue plerixafor for mobilization and collection of hematopoietic stem cells in patients with multiple myeloma and lymphoma. J Clin Apher. 2025; 40(3):e70026.","DOI":"10.1002\/jca.70026"},{"key":"88221","doi-asserted-by":"crossref","unstructured":"Mehl J, Akhoundova D, Bacher U. Daratumumab during myeloma induction therapy is associated with impaired stem cell mobilization and prolonged post-transplant hematologic recovery. Cancers (Basel). 2024; 16(10):1854.","DOI":"10.3390\/cancers16101854"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12958\/78968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12958\/79882","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12958\/78968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:06Z","timestamp":1794046206000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.288411","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}